NeoPharm CO. LTD (092730) — Cash Flow Reinvestment Rate
NeoPharm CO. LTD (092730) has a Cash Flow Reinvestment Rate of 0.25x as of September 2025, reinvesting ₩1.45 Billion (capex ₩446.60 Million plus investments ₩-1.00 Billion) from operating cash flow of ₩5.88 Billion. See 092730 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
NeoPharm CO. LTD Cash Flow Reinvestment Rate (2012–2024)
Historical reinvestment intensity for NeoPharm CO. LTD across 11 annual periods. For the full cash flow conversion analysis, see NeoPharm CO. LTD operating cash flow efficiency.
Annual Cash Flow Reinvestment Rate for NeoPharm CO. LTD (2012–2024)
Year-by-year capital reinvestment analysis for NeoPharm CO. LTD. See NeoPharm CO. LTD free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.50x | ₩9.30 Billion | ₩18.63 Billion | ₩3.08 Billion | ▼ -68.8% |
| 2023 | 1.60x | ₩37.18 Billion | ₩23.26 Billion | ₩20.83 Billion | ▲ +202.2% |
| 2022 | 0.53x | ₩9.61 Billion | ₩18.16 Billion | ₩806.43 Million | ▼ -29.7% |
| 2021 | 0.75x | ₩16.32 Billion | ₩21.68 Billion | ₩320.11 Million | ▲ +199.9% |
| 2020 | 0.25x | ₩4.29 Billion | ₩17.07 Billion | ₩285.62 Million | ▼ -90.7% |
| 2019 | 2.70x | ₩51.90 Billion | ₩19.22 Billion | ₩5.90 Billion | ▲ +398.5% |
| 2018 | 0.54x | ₩8.76 Billion | ₩16.18 Billion | ₩1.94 Billion | ▼ -48.2% |
| 2017 | 1.05x | ₩11.13 Billion | ₩10.65 Billion | ₩884.71 Million | ▲ +17.2% |
| 2016 | 0.89x | ₩8.17 Billion | ₩9.16 Billion | ₩1.40 Billion | ▲ +133.3% |
| 2015 | 0.38x | ₩2.33 Billion | ₩6.09 Billion | ₩786.89 Million | ▼ -81.5% |
| 2012 | 2.06x | ₩1.16 Billion | ₩564.34 Million | ₩172.47 Million | — |